title: A patient with acromegaly who showed remarkable improvement of hyperglycemia after treatment with octreotide.
abstract: A case with diabetes mellitus associated with growth hormone (GH)-producing pituitary adenoma is described. A 56-year-old woman who had been treated for diabetes mellitus for 3 years, was admitted for the treatment of hyperglycemia. She showed a few acromegalic features and her plasma GH level was 146 +/- 16 ng/ml. After improvement of plasma glucose level by insulin injection, octreotide therapy (100 micrograms/8 hours) was started. Seven days after the initiation of octreotide therapy, the fasting plasma glucose level was almost normalized without insulin injection. After the octreotide treatment, urinary C-peptide excretion was significantly decreased and the plasma GH level became within normal range. In this case, octreotide appears to have improved the insulin sensitivity by reducing the plasma GH level.
authors.affiliation: Department of Medicine III, Osaka University Medical School.
authors.forename: T
authors.initials: T
authors.lastname: Hirose
authors.forename: T
authors.initials: T
authors.lastname: Kuroda
authors.forename: M
authors.initials: M
authors.lastname: Otsuki
authors.forename: M
authors.initials: M
authors.lastname: Takagi
authors.forename: H
authors.initials: H
authors.lastname: Yamamoto
authors.forename: T
authors.initials: T
authors.lastname: Motomura
authors.forename: S
authors.initials: S
authors.lastname: Kurebayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Miyashita
authors.forename: M
authors.initials: M
authors.lastname: Koga
authors.forename: N
authors.initials: N
authors.lastname: Arita
authors.forename: T
authors.initials: T
authors.lastname: Hayakawa
authors.forename: T
authors.initials: T
authors.lastname: Kishimoto
authors.forename: S
authors.initials: S
authors.lastname: Kasayama
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D000236:Adenoma / Q000150:complications / Q000188:drug therapy; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000652:urine; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D005260:Female; D018149:Glucose Intolerance / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D007333:Insulin Resistance; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000150:complications / Q000188:drug therapy
chemical_list: D018931:Antineoplastic Agents, Hormonal; D001786:Blood Glucose; D002096:C-Peptide; D019382:Human Growth Hormone; D015282:Octreotide